- Home
- CHRS vs TVGN Comparison
CHRS vs TVGN Comparison
Compare CHRS & TVGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRS
- TVGN
- Stock Information
- Founded
- CHRS 2010
- TVGN 2020
- Country
- CHRS United States
- TVGN United States
- Employees
- CHRS N/A
- TVGN N/A
- Industry
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- TVGN Blank Checks
- Sector
- CHRS Health Care
- TVGN Finance
- Exchange
- CHRS Nasdaq
- TVGN Nasdaq
- Market Cap
- CHRS 84.2M
- TVGN 193.1M
- IPO Year
- CHRS 2014
- TVGN N/A
- Fundamental
- Price
- CHRS $0.83
- TVGN $1.24
- Analyst Decision
- CHRS Buy
- TVGN Strong Buy
- Analyst Count
- CHRS 3
- TVGN 1
- Target Price
- CHRS $4.68
- TVGN $10.00
- AVG Volume (30 Days)
- CHRS 1.3M
- TVGN 666.6K
- Earning Date
- CHRS 08-07-2025
- TVGN 08-13-2025
- Dividend Yield
- CHRS N/A
- TVGN N/A
- EPS Growth
- CHRS N/A
- TVGN N/A
- EPS
- CHRS N/A
- TVGN N/A
- Revenue
- CHRS $272,251,000.00
- TVGN N/A
- Revenue This Year
- CHRS N/A
- TVGN N/A
- Revenue Next Year
- CHRS $106.56
- TVGN N/A
- P/E Ratio
- CHRS N/A
- TVGN N/A
- Revenue Growth
- CHRS 19.87
- TVGN N/A
- 52 Week Low
- CHRS $0.66
- TVGN $0.26
- 52 Week High
- CHRS $2.43
- TVGN $3.09
- Technical
- Relative Strength Index (RSI)
- CHRS 56.33
- TVGN 51.87
- Support Level
- CHRS $0.73
- TVGN $1.19
- Resistance Level
- CHRS $0.82
- TVGN $1.27
- Average True Range (ATR)
- CHRS 0.04
- TVGN 0.05
- MACD
- CHRS 0.01
- TVGN -0.00
- Stochastic Oscillator
- CHRS 99.23
- TVGN 70.93
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.
About TVGN Tevogen Bio Holdings Inc. Common Stock
Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs or CTLs), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders.